Seamus C. Mulligan's most recent trade in Jazz Pharmaceuticals plc was a trade of 3,507 Ordinary Shares done . Disclosure was reported to the exchange on Aug. 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 3,507 | 1,179,613 (2%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Purchase of securities on an exchange or from another person at price $ 98.10 per share. | 09 May 2025 | 80,684 | 80,684 (0%) | 0% | 98.1 | 7,915,472 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Purchase of securities on an exchange or from another person at price $ 98.91 per share. | 09 May 2025 | 19,216 | 99,900 (0%) | 0% | 98.9 | 1,900,678 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Purchase of securities on an exchange or from another person at price $ 103.00 per share. | 09 May 2025 | 1,621 | 101,621 (0%) | 0% | 103.0 | 166,962 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Purchase of securities on an exchange or from another person at price $ 99.71 per share. | 09 May 2025 | 100 | 100,000 (0%) | 0% | 99.7 | 9,971 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 3,731 | 1,176,106 (2%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 3,075 | 1,172,375 (2%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.76 per share. | 08 Jun 2023 | 4,500 | 1,169,300 (2%) | 0% | 81.8 | 367,920 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 4,500 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 59.13 per share. | 04 Mar 2023 | 4,500 | 1,164,800 (2%) | 0% | 59.1 | 266,085 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2023 | 4,500 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2022 | 2,561 | 1,160,300 (2%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Seamus C. Mulligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2021 | 2,246 | 1,157,739 (2%) | 0% | 0 | Ordinary Shares |